Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 153-158

  de Vries van der Weij, Jitske ^a,b   Zadelaar, Susanne ^a   Toet, Karin ^a   Havekes, Louis M ^a,b   Kooistra, Teake ^a   Rensen, Patrick C N ^c  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Endocrinology   (Netherlands)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; Lesion stability; Lipoproteins

Indexed keywords

APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; E-SELECTIN; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; MICE; SERUM AMYLOID A PROTEIN;

EID: 68949207221     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.02.038     Document Type: Article

References (28)

1. Ha Y.C., Calvert G.D., and Barter P.J. In vivo metabolism of esterified cholesterol and apoproteins in rabbit plasma low density lipoproteins. Atherosclerosis 34 (1979) 451-455
2. Moriyama Y., Okamura T., Inazu A., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27 (1998) 659-667
3. Westerterp M., van der Hoogt C.C., de H.W., et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
4. Plump A.S., Masucci-Magoulas L., Bruce C., et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999) 1105-1110
5. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Circulation 110 (2004) 1418-1423
6. de Grooth G.J., Smilde T.J., Van W.S., et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173 (2004) 261-267
7. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 338 (1998) 86-93
8. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., and Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101 (2000) 1907-1912
9. Borggreve S.E., Hillege H.L., Wolffenbuttel B.H., et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91 (2006) 3382-3388
10. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
11. Thompson A., Di A.E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299 (2008) 2777-2788
12. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
13. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
14. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
15. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
16. Forrest M.J., Bloomfield D., Briscoe R.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154 (2008) 1465-1473
17. de Haan W., de Vries-van der Weij J., van der Hoorn J.W., et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 117 (2008) 2515-2522
18. Faust R.A., Tollefson J.H., Chait A., and Albers J.J. Regulation of LTP-I secretion from human monocyte-derived macrophages by differentiation and cholesterol accumulation in vitro. Biochim Biophys Acta 1042 (1990) 404-409
19. Gotoda T., Kinoshita M., Shimano H., et al. Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem Biophys Res Commun 194 (1993) 519-524
20. Ishikawa Y., Ito K., Akasaka Y., et al. The distribution and production of cholesteryl ester transfer protein in the human aortic wall. Atherosclerosis 156 (2001) 29-37
21. Westerterp M., de Haan W., Berbee J.F., Havekes L.M., and Rensen P.C. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 47 (2006) 1203-1211
22. Koopman J., Maas A., Rezaee F., et al. Fibrinogen and atherosclerosis: a study in transgenic mice. Fibrinolysis Proteol 11 (1997) 19-21
23. Rein D., Schijlen E., Kooistra T., et al. Transgenic flavonoid tomato intake reduces C-reactive protein in human C-reactive protein transgenic mice more than wild-type tomato 2. J Nutr 136 (2006) 2331-2337
24. Zadelaar A.S., Boesten L.S., Jukema J.W., et al. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2560-2566
25. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
26. Huang Z., Inazu A., Nohara A., Higashikata T., and Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103 (2002) 587-594
27. Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., and Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 (2008) 2506-2514
28. Vergeer M., Bots M.L., van Leuven S.I., et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522